NUC-7000 / NuCana - LARVOL DELTA

Dr Borthakur on the SELECT MDS-1 Trial in Newly Diagnosed MDS (OncLive) - "Gautam Borthakur, MD...discusses the ongoing phase 3 SELECT MDS-1 trial (NCT04797780) in patients with newly diagnosed myelodysplastic syndromes (MDS)....Although targeted therapies have been developed for patients with MDS harboring IDH1, IDH2, or FLT3 mutations, significant progress has not been made in developing novel therapies for patients with higher-risk MDS, and the SELECT MDS-1 trial will further investigate the use of tamibarotene for the subset of patients with RARA positivity, Borthakur concludes."

Video

Management of AML: FLT3 Inhibitors and BCL2 Inhibitors (OncLive) - "Harry P. Erba, MD, PhD: Eunice, why don’t you discuss the data that you presented on gilteritinib?...Harry P. Erba, MD, PhD: It is about getting in remission and staying in remission on drugs they can tolerate. What we do not know is the combinations vs sequencing and what the best way to do that is."

Video